Skip to main content

Table 2 Development of patient-derived breast tumor xenografts in SCID mice

From: Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients

 

Total

ER+

ER-

Triple negative

Patients samples received

29

17

12

7

Samples that grew tumors in mice after first implantation

8

4

4

4

Take rate

27.59%

23.53%

33.33%

57.14%

Samples that established a stable and propagatable tumor in mice (successful growth in subsequent passages)

6

2

4

4

Stable take rate

20.69%

11.76%

33.33%

57.14%

  1. Numbers of patient samples implanted in the mammary fat pad of SCID mice and take rates for successful growth in the mice. For some of the samples, a tumor grew only on the first implantation. We call stable take-rate the percentage of samples that established tumors in mice that were capable of growing tumors in subsequent passages.